\n<\/p>\n
Annual sales at Almac, the Craigavon-based pharmaceutical firm, topped \u00a31bn for the first time in 2024.<\/p>\n
Total revenues for the year ending 30 September were \u00a31.027bn, a \u00a369.5m (7%) increase from 2023.<\/p>\n
Pre-tax profits rose by 27% to \u00a3119m, which is up from \u00a393.8m in the previous year.<\/p>\n
Almac’s main line of business is providing services, such as manufacturing and distribution, to major global pharmaceutical firms.<\/p>\n<\/div>\n
It also develops its own drugs, for example earlier this month it reached an agreement to licence a cancer treatment to a Taiwanese firm for further development and commercialisation.<\/p>\n
The company continued to grow its workforce over the last year and now employs about 7,700 people across its global operations.<\/p>\n
Alan Armstrong, Almac’s group chairman and chief executive, said: “Today’s results mark another successful year of growth for Almac.<\/p>\n
“As a privately-owned and independent company, we re-invest all our profits back into the business, enabling us to innovate and expand to meet the growing needs of our global clients, working in partnership to advance human health.”<\/p>\n
Those investments have included growing the company’s production and distribution facilities in the US and Singapore.<\/p>\n
Almac has now joined a small number of Northern Ireland-based firms that boast an annual turnover of \u00a31bn or more.<\/p>\n
They include Graham construction and W&R Barnett, a commodities and manufacturing group.<\/p>\n<\/div>\n